Optimising Multimodality Treatment of Resectable Oesophago-Gastric Adenocarcinoma.

ABSTRACT: Oesophago-gastric adenocarcinoma remains a leading cause of cancer-related morbidity and mortality worldwide. Although there has been an enormous progress in the multimodality management of resectable oesophago-gastric adenocarcinoma, most patients still develop a recurrent disease that eventually becomes resistant to systemic therapy. Currently, there is no global consensus on the optimal multimodality approach and there are variations in accepted standards of care, ranging from preoperative chemoradiation to perioperative chemotherapy and, more recently, adjuvant immune checkpoint inhibitors. Ongoing clinical trials are aimed to directly compare multimodal treatment options as well as the additional benefit of targeted therapies and immunotherapies. Furthermore, our understanding of the

SUBMITTER: Suwaidan AA 

PROVIDER: S-EPMC8833621 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature